Key result
Waon therapy for 2 weeks did not significantly improve circulating levels of BNP, aldosterone, or CNP compared to control in patients with chronic heart failure.
Why the study?
Does Waon therapy improve neurohumoral factors (BNP, aldosterone, CNP) in hospitalized patients with chronic heart failure?
RCT (n=150)
Randomized
Yes
Does Waon therapy improve neurohumoral factors (BNP, aldosterone, CNP) in hospitalized patients with chronic heart failure?
Waon therapy did not significantly improve overall neurohumoral biomarker levels in chronic heart failure patients over 2 weeks, though subgroup analyses suggest it may enhance the effects of RAAS modulators.
Answers are grounded in this paper and cite their sources.
Waon therapy offers no neurohumoral benefit in chronic HF; does not support adoption and challenges prior positive observations.
BACKGROUND: Heart failure (HF) is a disease of neurohumoral dysfunction and current pharmacological therapies for HF have not improved mortality rates, thus requiring additional new strategies. Waon therapy for HF patients may be a complementary strategy with peripheral vasodilation via nitric oxide. We hypothesized that Waon therapy would improve neurohumoral factors, such as natriuretic peptides (NP) and the renin-angiotensin-aldosterone system (RAAS) in HF. METHODS AND These changes were not observed in the control group. CONCLUSIONS: Waon therapy may accelerate the favorable actions of RAAS modulators in HF. (WAON-CHF Study: UMIN000006705).
No takes yet. Share an insight, caveat, or question.
Ichiki et al. (2017) conducted an RCT in Chronic Heart Failure (n=150). Waon therapy vs. Control (observation) was evaluated on Change in B-type natriuretic peptide (BNP) level (pg/mL) (p=0.86). Waon therapy for 2 weeks did not significantly improve circulating levels of BNP, aldosterone, or CNP compared to control in patients with chronic heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: